Zurück zu Ihrem Suchergebnis

Beschreibung

SLAM family member 7 (UniProt: Q9NQ25, also known as SLAMF7, CD2 subset 1, CD2-like receptor-activating cytotoxic cells, CRACC, Membrane protein FOAP-12, Novel Ly9, Protein 19A, CD319) is encoded by the SLAMF7 (also known as CS1, UNQ576/PRO1138) gene (Gene ID: 57823) in human. SLAMF-7 is a single-pass type I membrane protein that is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Expression has also been detected in multiple myeloma cells, NK cells, activated B-cells, and NK-cell line, but not in promyelocytic, B-, or T-cell lines. It serves as a receptor on immune cells, including natural killer (NK) cells. SLAMF7 is reported to mediate both activating and inhibitory effects on NK cells, depending on the expression of adaptor EAT-2. In cells lacking EAT-2 it mediates inhibition via SHIP-1, which is recruited via Tyr 261 of SLAMF7. SLAMF7 is shown to be involved in phagocytosis of hematopoietic tumor cells independent of signaling lymphocyte activation molecule-associated protein (SAP) adaptors, but depends on its ability to interact with integrin Mac-1 and utilizes signals involving ITSM motif (aa 302-307). SLAMF7 is synthesized with a signal peptide (aa 1-22), which is subsequently removed to generate the mature form that has an extracellular domain (aa 23-226), a short transmembrane domain (aa 227-247), and a cytoplasmic tail (aa 248-335). Seven different isoforms of SLAMF7 have been described that are produced by alternative splicing. Clone 162 is shown to block the augmented capacity of human blood-derived macrophages to engulf Raji cells in response to Anti-CD47 antibodies. (Ref.: Guo, H., et al. (2015). Mol. Cell. Biol. 35 (1), 41-51, Chen, J., et al. (2017). Nature 544 (7651), 493-497).